Healthcare company: Fresenius reduces its stake in Fresenius Medical Care
Fresenius reduces its stake in the dialysis provider by almost three percent. The proceeds from the sale of around eight million shares do not all go into more growth.
Fresenius, a German healthcare company, has reduced its stake in dialysis provider Fresenius Medical Care (FMC) by selling 7.8 million shares to institutional investors for approximately 300 million euros. This represents around 2.9% of FMC's capital, bringing Fresenius' stake down from 27.8% to around 25%. The sale is expected to result in a low to mid-double-digit million euro book gain, which will be reflected in Fresenius' third-quarter 2026 results. The proceeds will be used to invest in growth platforms and pay off debt.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
